Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 15.07.2024 1 Ann Surg 6 Ann Surg Oncol 1 BMC Cancer 1 Cancer 2 Cancer Lett 1 Cancer Sci 1 Chest 1 Clin Cancer Res 3 Clin Lung Cancer 2 Eur J Cancer 1 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Clin Oncol 2 J Surg Oncol 2 J Thorac Cardiovasc Surg 6 J Thorac Oncol 9 Lung Cancer 1 Nat Med 1 Oncogene 1 Oncologist 3 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg

1. BOAM T, Rogoyski BG, Jawaid W, Losty PD, et al
   Do Children With Osteosarcoma Benefit From Pulmonary Metastasectomy?: A Systematic Review of Published Studies and "Real World" Outcomes.
   Ann Surg. 2024;280:235-240.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. SHAH SK, Krishnan V, Khan AA, Fass L, et al
   Women are Underrepresented in Non-small Cell Lung Cancer Clinical Trials: A Systematic Review.
   Ann Surg Oncol. 2024 Jul 10. doi: 10.1245/s10434-024-15720.
   PubMed         Abstract available
   
   
3. SHAH SK, Khan AA, Alex GC
   ASO Author Reflections: Getting a Seat at the Table-A Call for Equitable Inclusion of Women in Lung Cancer Clinical Trials.
   Ann Surg Oncol. 2024 Jul 8. doi: 10.1245/s10434-024-15778.
   PubMed        
   
   
4. TANE S
   The Crucial Value of Glutathione Peroxidase 2 to Understand the 'Two-Faced' Role of Reactive Oxygen Species in Lung Adenocarcinoma.
   Ann Surg Oncol. 2024;31:4849-4850.
   PubMed        
   
   
5. HASHINOKUCHI A, Matsubara T, Ono Y, Shunichi S, et al
   ASO Visual Abstract: Clinical and Prognostic Significance of Glutathione Peroxidase 2 in Lung Adenocarcinoma.
   Ann Surg Oncol. 2024;31:5098.
   PubMed        
   
   
6. WOO W, Park CH, Lee J, Moon DH, et al
   Left Upper Division Segmentectomy Compared with Lobectomy for Lung Expansion and Bronchus Tortuosity.
   Ann Surg Oncol. 2024;31:5021-5027.
   PubMed         Abstract available
   
   
7. HASHINOKUCHI A, Matsubara T, Takenaka T, Yoshizumi T, et al
   ASO Author Reflections: Impact of Glutathione Peroxidase 2 (GPX2) in Lung Adenocarcinoma.
   Ann Surg Oncol. 2024;31:5092-5093.
   PubMed        
   
   

   
   BMC Cancer

8. MA L, Li R, Liu X, Yu W, et al
   Prognostic and clinicopathological significance of tertiary lymphoid structure in non-small cell lung cancer: a systematic review and meta-analysis.
   BMC Cancer. 2024;24:815.
   PubMed         Abstract available
   
   

   
   Cancer

9. WANG Y, Kondrat K, Adhikari J, Nguyen Q, et al
   Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database-based study.
   Cancer. 2024 Jul 10. doi: 10.1002/cncr.35476.
   PubMed         Abstract available
   
   

   
   Cancer Lett

10. SINGH D, Qiu Z, Jonathan SM, Fa P, et al
    PP2A B55alpha Inhibits Epithelial-Mesenchymal Transition Via Regulation of Slug Expression in Non-Small Cell Lung Cancer.
    Cancer Lett. 2024 Jul 8:217110. doi: 10.1016/j.canlet.2024.217110.
    PubMed         Abstract available
    
    
11. LI X, Shang S, Wu M, Song Q, et al
    Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis.
    Cancer Lett. 2024;598:217096.
    PubMed         Abstract available
    
    

    
    Cancer Sci

12. WANG Y, Ma L, Chen Y, Yun W, et al
    Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.
    Cancer Sci. 2024;115:2184-2195.
    PubMed         Abstract available
    
    

    
    Chest

13. MEYERS PM, Kammer MN
    Exploring the Intersection of Reproductive Factors and Lung Cancer Risk in Female Patients.
    Chest. 2024;166:10-11.
    PubMed        
    
    

    
    Clin Cancer Res

14. SCALERA S, Ricciuti B, Marinelli D, Mazzotta M, et al
    Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy.
    Clin Cancer Res. 2024 Jul 9. doi: 10.1158/1078-0432.CCR-24-0626.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

15. WU X, Stabile LP, Burns TF
    The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2024 Jun 10:S1525-7304(24)00124.
    PubMed         Abstract available
    
    
16. KLEEMISS M, Muller CE, Schneider M, Strotmann R, et al
    Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report.
    Clin Lung Cancer. 2024 May 25:S1525-7304(24)00109.
    PubMed        
    
    
17. SHAH AT, Blanchard I, Padda SK, Wakelee HA, et al
    Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2024 Jun 19:S1525-7304(24)00133.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

18. PARK S, Park S, Kim TM, Kim S, et al
    Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer.
    Eur J Cancer. 2024;208:114206.
    PubMed         Abstract available
    
    
19. FELIP E, Metro G, Soo RA, Wolf J, et al
    Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
    Eur J Cancer. 2024;208:114182.
    PubMed         Abstract available
    
    

    
    Int J Cancer

20. YIN M, Liu L, Yan Y, Wang H, et al
    A targeting nanoplatform for chemo-photothermal synergistic therapy of small-cell lung cancer.
    Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35065.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

21. EDWARDS DM, Schonewolf CA, Rice JD, Schipper M, et al
    Phase II Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2024 Jul 4:S0360-3016(24)00749.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

22. HE L, Chen H, Ruan B, He L, et al
    UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway.
    J Cancer Res Clin Oncol. 2024;150:335.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

23. PEROL M
    TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A Fading Hope?
    J Clin Oncol. 2024 Jul 10:JCO2401043. doi: 10.1200/JCO.24.01043.
    PubMed        
    
    

    
    J Surg Oncol

24. PORTO DM, Costa GJ, Torres LC, Casarini DE, et al
    Immune checkpoint expression as prognostic biomarker candidates in non-small cell lung carcinoma patients.
    J Surg Oncol. 2024 Jul 7. doi: 10.1002/jso.27763.
    PubMed         Abstract available
    
    
25. MAMEDE I, Ribeiro L, Stecca C, Escalante-Romero L, et al
    Survival and pulmonary function in stage IA non-small cell lung cancer after sublobar resection versus lobectomy: An updated meta-analysis.
    J Surg Oncol. 2024 Jul 9. doi: 10.1002/jso.27767.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

26. TSUBOKAWA N, Mimae T, Saeki A, Miyata Y, et al
    Feasibility and Comparative Prognosis of Segmentectomy vs. Lobectomy in Centrally Located Small and Solid Dominant cN0 Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2024 Jul 3:S0022-5223(24)00538.
    PubMed         Abstract available
    
    
27. LIN Y
    Accurate predictor of occult mediastinal nodal metastasis in stage I lower-lobe non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2024 Jul 5:S0022-5223(24)00381.
    PubMed        
    
    

    
    J Thorac Oncol

28. MOCHIZUKI A, Shiraishi K, Honda T, Higashiyama RI, et al
    Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis.
    J Thorac Oncol. 2024;19:984-994.
    PubMed         Abstract available
    
    
29. JUN S, Shukla NA, Durm G, Hui AB, et al
    Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Jul 4:S1556-0864(24)00664.
    PubMed         Abstract available
    
    
30. AFRIYIE-MENSAH JS, Dadzie MA, Vanderpuye VDNK, Calys-Tagoe B, et al
    Lung Cancer in Ghana.
    J Thorac Oncol. 2024;19:966-972.
    PubMed        
    
    
31. SHEN LT, Chen HL
    Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia.
    J Thorac Oncol. 2024;19:e13-e14.
    PubMed        
    
    
32. YANG JJ, Wen W, Zheng W, Shu XO, et al
    "Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia".
    J Thorac Oncol. 2024;19:e14-e15.
    PubMed        
    
    
33. LIN YL, Wang GS, Wei JC
    Rheumatoid Arthritis and Risk of Lung Cancer.
    J Thorac Oncol. 2024;19:e15-e16.
    PubMed        
    
    

    
    Lung Cancer

34. ERNST SM, van Marion R, von der Thusen JH, Dubbink HJ, et al
    Exploring the use of circulating tumor DNA for mutational signature analysis.
    Lung Cancer. 2024;193:107844.
    PubMed        
    
    
35. FRANK AL, van Zandwijk N
    Asbestos history and use.
    Lung Cancer. 2024;193:107828.
    PubMed         Abstract available
    
    
36. BORGHAEI H, Pundole X, Sangare L, Anderson E, et al
    Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study.
    Lung Cancer. 2024;193:107819.
    PubMed         Abstract available
    
    
37. ARMATO SG 3RD, Katz SI, Frauenfelder T, Jayasekera G, et al
    Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group.
    Lung Cancer. 2024;193:107832.
    PubMed         Abstract available
    
    
38. SAW SPL, Low YF, Lai GGY, Chan LL, et al
    Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
    Lung Cancer. 2024;193:107856.
    PubMed         Abstract available
    
    
39. DE BRUYCKER A, Schneiders F, Gulstene S, Moghanaki D, et al
    Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights.
    Lung Cancer. 2024;193:107848.
    PubMed         Abstract available
    
    
40. YOSHIZAKI C, Yoshida Y, Nohmi S, Go Y, et al
    EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report.
    Lung Cancer. 2024;194:107869.
    PubMed         Abstract available
    
    
41. LI R, Xu Y, Zhao J, Zhang L, et al
    Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis.
    Lung Cancer. 2024;194:107884.
    PubMed         Abstract available
    
    
42. PONS-TOSTIVINT E, Ezzedine R, Goronflot T, Crequit P, et al
    Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study.
    Lung Cancer. 2024;194:107887.
    PubMed         Abstract available
    
    

    
    Nat Med

43. CHENG Y, Chen J, Zhang W, Xie C, et al
    Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
    Nat Med. 2024 Jul 11. doi: 10.1038/s41591-024-03132.
    PubMed         Abstract available
    
    

    
    Oncogene

44. WANG Z, Lei Z, Wang Y, Wang S, et al
    Bone-metastatic lung adenocarcinoma cells bearing CD74-ROS1 fusion interact with macrophages to promote their dissemination.
    Oncogene. 2024;43:2215-2227.
    PubMed         Abstract available
    
    

    
    Oncologist

45. MEHTA GU, Vellanki PJ, Ren Y, Amatya AK, et al
    FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
    Oncologist. 2024 Jul 6:oyae151. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

46. PARK J, Rho MJ, Moon MH
    Enhanced deep learning model for precise nodule localization and recurrence risk prediction following curative-intent surgery for lung cancer.
    PLoS One. 2024;19:e0300442.
    PubMed         Abstract available
    
    
47. LOTFI F, Rashidian H, Hadji M, Mohebbi E, et al
    Exposure to second-hand smoke and risk of lung cancer among Iranian population: A multicenter case-control study.
    PLoS One. 2024;19:e0306517.
    PubMed         Abstract available
    
    
48. HAO H, Maeda Y, Fukazawa T, Yamatsuji T, et al
    Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer.
    PLoS One. 2024;19:e0307052.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

49. SHAN L, Wang W, Du L, Li D, et al
    SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.
    Proc Natl Acad Sci U S A. 2024;121:e2401834121.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.